73 related articles for article (PubMed ID: 18490101)
21. Presence of potent transcriptional activation domains in the predisposing tuberous sclerosis (Tsc2) gene product of the Eker rat model.
Tsuchiya H; Orimoto K; Kobayashi K; Hino O
Cancer Res; 1996 Feb; 56(3):429-33. PubMed ID: 8564946
[TBL] [Abstract][Full Text] [Related]
22. [Experimental study of MAT1 gene silencing mediated by siRNA in pancreatic cancer].
Liu JP; Yuan SZ; Zhang SN
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(38):2719-23. PubMed ID: 18167254
[TBL] [Abstract][Full Text] [Related]
23. Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice.
Murata N; Takashima Y; Toyoshima K; Yamamoto M; Okada H
J Control Release; 2008 Mar; 126(3):246-54. PubMed ID: 18215787
[TBL] [Abstract][Full Text] [Related]
24. Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer.
Jonson AL; Rogers LM; Ramakrishnan S; Downs LS
Gynecol Oncol; 2008 Nov; 111(2):356-64. PubMed ID: 18755502
[TBL] [Abstract][Full Text] [Related]
25. Delivery of small interfering RNA with a synthetic collagen poly(Pro-Hyp-Gly) for gene silencing in vitro and in vivo.
Adachi T; Kawakami E; Ishimaru N; Ochiya T; Hayashi Y; Ohuchi H; Tanihara M; Tanaka E; Noji S
Dev Growth Differ; 2010 Oct; 52(8):693-9. PubMed ID: 20874713
[TBL] [Abstract][Full Text] [Related]
26. Caspase 8 small interfering RNA prevents acute liver failure in mice.
Zender L; Hutker S; Liedtke C; Tillmann HL; Zender S; Mundt B; Waltemathe M; Gosling T; Flemming P; Malek NP; Trautwein C; Manns MP; Kuhnel F; Kubicka S
Proc Natl Acad Sci U S A; 2003 Jun; 100(13):7797-802. PubMed ID: 12810955
[TBL] [Abstract][Full Text] [Related]
27. Short interfering RNA (siRNA): tool or therapeutic?
Cejka D; Losert D; Wacheck V
Clin Sci (Lond); 2006 Jan; 110(1):47-58. PubMed ID: 16336204
[TBL] [Abstract][Full Text] [Related]
28. RNA interference in vivo: toward synthetic small inhibitory RNA-based therapeutics.
de Fougerolles A; Manoharan M; Meyers R; Vornlocher HP
Methods Enzymol; 2005; 392():278-96. PubMed ID: 15644187
[TBL] [Abstract][Full Text] [Related]
29. [Cancer genetics of TSC2 gene mutant(Eker) rat model].
Hino O
Nihon Rinsho; 2000 Jun; 58(6):1255-61. PubMed ID: 10879050
[TBL] [Abstract][Full Text] [Related]
30. A tightly regulated and reversibly inducible siRNA expression system for conditional RNAi-mediated gene silencing in mammalian cells.
Wu RH; Cheng TL; Lo SR; Hsu HC; Hung CF; Teng CF; Wu MP; Tsai WH; Chang WT
J Gene Med; 2007 Jul; 9(7):620-34. PubMed ID: 17486668
[TBL] [Abstract][Full Text] [Related]
31. Synergistic antitumor activity of XIAP-shRNA and TRAIL expressed by oncolytic adenoviruses in experimental HCC.
Pan Q; Liu B; Liu J; Cai R; Liu X; Qian C
Acta Oncol; 2008; 47(1):135-44. PubMed ID: 17934893
[TBL] [Abstract][Full Text] [Related]
32. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo.
Minakuchi Y; Takeshita F; Kosaka N; Sasaki H; Yamamoto Y; Kouno M; Honma K; Nagahara S; Hanai K; Sano A; Kato T; Terada M; Ochiya T
Nucleic Acids Res; 2004 Jul; 32(13):e109. PubMed ID: 15272050
[TBL] [Abstract][Full Text] [Related]
33. Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model.
Bisanz K; Yu J; Edlund M; Spohn B; Hung MC; Chung LW; Hsieh CL
Mol Ther; 2005 Oct; 12(4):634-43. PubMed ID: 16039164
[TBL] [Abstract][Full Text] [Related]
34. Suppression of the neoplastic phenotype by replacement of the Tsc2 gene in Eker rat renal carcinoma cells.
Orimoto K; Tsuchiya H; Kobayashi T; Matsuda T; Hino O
Biochem Biophys Res Commun; 1996 Feb; 219(1):70-5. PubMed ID: 8619830
[TBL] [Abstract][Full Text] [Related]
35. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine.
Choi YS; Lee JY; Suh JS; Kwon YM; Lee SJ; Chung JK; Lee DS; Yang VC; Chung CP; Park YJ
Biomaterials; 2010 Feb; 31(6):1429-43. PubMed ID: 19954842
[TBL] [Abstract][Full Text] [Related]
36. Small interfering RNA for experimental cancer therapy.
Tong AW; Zhang YA; Nemunaitis J
Curr Opin Mol Ther; 2005 Apr; 7(2):114-24. PubMed ID: 15844618
[TBL] [Abstract][Full Text] [Related]
37. Survivin knockdown by short hairpin RNA abrogates the growth of human hepatocellular carcinoma xenografts in nude mice.
Zhang R; Ma L; Zheng M; Ren J; Wang T; Meng Y; Zhao J; Jia L; Yao L; Han H; Li K; Yang A
Cancer Gene Ther; 2010 Apr; 17(4):275-88. PubMed ID: 19876077
[TBL] [Abstract][Full Text] [Related]
38. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
Dong AQ; Kong MJ; Ma ZY; Qian JF; Fan JQ; Xu XH
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1506-9. PubMed ID: 17785094
[TBL] [Abstract][Full Text] [Related]
39. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice.
Kobayashi T; Minowa O; Kuno J; Mitani H; Hino O; Noda T
Cancer Res; 1999 Mar; 59(6):1206-11. PubMed ID: 10096549
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic potential of RNA interference against cancer.
Takeshita F; Ochiya T
Cancer Sci; 2006 Aug; 97(8):689-96. PubMed ID: 16863503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
